Top Markets
#1 Black Phoenix Black Phoenix +197.93%
#2 Islamic Coin Islamic Coin +157.91%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +50.78%
#5 BasedHype BasedHype +32.69%
#6 Acurast Acurast +23.82%
#7 Cryptopia Cryptopia +21.79%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +19.28%
#9 Akedo Akedo +19.20%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Biocept, Inc. Biocept, Inc.

Biocept, Inc.

BIOC
Classifica tra le azioni #41379
Biocept, Inc. is a company specializing in molecular diagnostics for cancer,... Biocept, Inc. is a company specializing in molecular diagnostics for cancer, primarily focused on developing and commercializing advanced diagnostic assays based on proprietary technology. These tests analyze circulating tumor cells (CTCs) and cell-free tumor DNA and RNA (ctDNA/ctRNA), primarily using standard blood samples. These assays furnish crucial insights to healthcare professionals, enabling them to identify specific genetic changes (oncogenic alterations) that qualify certain cancer patients for targeted therapies. This information is vital throughout the patient journey: at initial diagnosis, during disease progression, and for ongoing monitoring to detect the emergence of treatment resistance. Their diagnostic portfolio extends to various solid tumor types, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. Beyond blood-based diagnostics, Biocept offers specialized testing services for cerebrospinal fluid (CSF), analyzing tumor cells, ctDNA, and ctRNA. These services cater to a broad spectrum of medical specialists, such as medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, and pathologists. Furthermore, the company supports pharmaceutical and biopharmaceutical companies, along with clinical research organizations (CROs), through its clinical trial and research services. Additionally, Biocept provides RT-PCR testing for COVID-19. In strategic partnerships, Biocept collaborates with CLEARED4 on a system designed to track and manage COVID-19 testing requirements and results for clients. Another collaboration involves Protean BioDiagnostics, Inc., focusing on research into the efficacy of Biocept's proprietary Target Selector molecular assay for determining EGFR status in non-small cell lung cancer (NSCLC) patients. Established in 1997, Biocept, Inc. operates from its headquarters in San Diego, California.
Prezzo delle azioni
$0.053
Ultima sincronizzazione: 2023-11-21
Capitalizzazione di mercato
$23.67K
Variazione (1 giorno)
-11.67%
Variazione (1 anno)
0.00%
Paese
US
Scambia Biocept, Inc. (BIOC)

Categoria

Healthcare
Rapporto P/E per Biocept, Inc. (BIOC)
Rapporto P/E al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Biocept, Inc., il rapporto P/E attuale (TTM) è 0. Alla fine del 2026, il rapporto P/E era 0.
Storico del rapporto P/E per Biocept, Inc. da 2026 a 2026
Rapporto P/E alla fine di ogni anno
Anno Rapporto P/E Cambia
Non abbastanza dati per le date fornite.
Rapporto P/E per aziende simili o concorrenti
Azienda P/E Ratio Differenza del P/E Ratio Il paese
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 30.84 -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 34.53 -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 40.90 -
US
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -164.27 -
US
Come leggere un P/E ratio?

Il rapporto Prezzo/Utile (P/E) misura la relazione tra il prezzo delle azioni di una società e i suoi utili per azione.
Un P/E basso ma positivo indica un'azienda che genera alti profitti rispetto alla sua valutazione attuale e potrebbe essere sottovalutata. Un'azienda con un P/E negativo elevato (vicino allo 0) segnala forti perdite rispetto alla valutazione.

Le aziende con un P/E superiore a 30 o negativo sono generalmente considerate "azioni di crescita", cioè ci si aspetta che crescano o diventino redditizie.

Le aziende con un P/E positivo inferiore a 10 sono considerate "azioni di valore", ossia già molto redditizie ma con scarse prospettive di crescita.